Coeptis Therapeutics Inc

As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc. in a reverse merger transaction. The company, together with its subsidiaries, operates as a biopharmaceutical and technology company developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its portfolio includes an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage unmodified natural killer cell therapy. The pipeline consists of CD38-GEAR-NK for CD38-related cancers, CD38-Diagnostic for screening candidates for anti-CD38 mAb therapy, and SNAP-CAR, a CAR therapy for cancer. The company also offers drugs for acute myeloid leukemia and acute respiratory diseases, and has a co-development agreement with Vici Health Sciences, LLC for CPT60621 for Parkinson's Disease. Founded in 2017, it is headquartered in Wexford, Pennsylvania.